Existing Drug Could Target Neuroinflammation in Alzheimer's Patients
Researchers found that blocking the P2X7 receptor cut inflammatory cytokine release in human brain tissue, pointing to a possible treatment for conditions with no effective drug options.
9 Articles
9 Articles
Drug target could block brain inflammation linked to Alzheimer’s and Parkinson’s
Blocking a receptor called P2X7 significantly reduced inflammation in human brain tissue, revealing a potential new treatment strategy for neurological and psychiatric disorders. The discovery could help researchers repurpose existing drugs for conditions including traumatic brain injury, Alzheimer’s, Parkinson’s, depression, and schizophrenia.
Existing drug could target neuroinflammation in Alzheimer's patients
Inflammatory conditions in the brain, including traumatic brain injury and degenerative diseases like Alzheimer's could be targeted with an existing drug thanks to new research that shows it can work in brain cells.
A study conducted by the British University of Birmingham revealed a possible mechanism for reducing neuroinflammation in the brain, which could contribute to the development of future treatments for diseases and disorders associated with neuroinflammation, including Alzheimer ' s and Parkinson ' s diseases and brain trauma. The results of the study published by the University via its website yesterday Sunday, showed that blocking the …
Brain tissue removed during surgery reveals potential way to curb inflammation linked to Alzheimer's
Inflammatory conditions in the brain, including traumatic brain injury and degenerative diseases like Alzheimer's, could be targeted with an existing drug thanks to new research that shows it can work in brain cells.
Anti-Inflammatory Drug Target for Alzheimer’s, TBI, and Neurodegenerative Disease Identified
The results of research headed by a team at the University of Birmingham suggest that inflammatory conditions in the brain, including traumatic brain injury (TBI) and degenerative diseases such as Alzheimer’s disease and Parkinson’s disease, could be targeted with an existing developmental drug. Using live cultures of human brain cells and slices of brain tissue obtained during neurosurgery, the researchers, headed by Nicholas Barnes, PhD, profe…
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
